eicosapentaenoic acid ethyl ester has been researched along with Carotid Artery Diseases in 2 studies
Carotid Artery Diseases: Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cawood, AL | 1 |
| Ding, R | 1 |
| Napper, FL | 1 |
| Young, RH | 1 |
| Williams, JA | 1 |
| Ward, MJ | 1 |
| Gudmundsen, O | 1 |
| Vige, R | 1 |
| Payne, SP | 1 |
| Ye, S | 1 |
| Shearman, CP | 1 |
| Gallagher, PJ | 1 |
| Grimble, RF | 1 |
| Calder, PC | 1 |
| Zampelas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability[NCT00294216] | Phase 3 | 121 participants | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for eicosapentaenoic acid ethyl ester and Carotid Artery Diseases
| Article | Year |
|---|---|
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capsules; Carotid Artery Diseases; Chi-Square | 2010 |
1 other study available for eicosapentaenoic acid ethyl ester and Carotid Artery Diseases
| Article | Year |
|---|---|
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Topics: Administration, Oral; Capsules; Carotid Artery Diseases; Dietary Supplements; Docosahexaenoic Acids; | 2010 |